A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension
Addpharma Inc.
251 participants
Jul 31, 2024
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Per Oral, 1 Tablet, Once a day for 8 weeks
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06441630